| Mr Adam Alan Vanregenmorter, MD | |
|
2827 Fort Missoula Rd, Missoula, MT 59804-7408 | |
| (406) 327-4330 | |
| Not Available |
| Full Name | Mr Adam Alan Vanregenmorter |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 17 Years |
| Location | 2827 Fort Missoula Rd, Missoula, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982820478 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 25578 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Patrick Hospital | Missoula, MT | Hospital |
| Clark Fork Valley Hospital | Plains, MT | Hospital |
| Providence St Joseph Medical Center | Polson, MT | Hospital |
| Marcus Daly Memorial Hospital - Cah | Hamilton, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Mt | 6608786306 | 272 |
News Archive
MR Solutions' latest compact preclinical, multi-modality MRI systems will be on display at the 14th European Molecular Imaging Meeting (EMIM 2019) being held at the Scottish Event Campus in Glasgow on 19 to 22 March, 2019.
The startlingly clear images displayed by high definition televisions have attracted the attention of sports enthusiasts, movie fanatics, and video gamers. Now some surgeons at the Virginia Commonwealth University Medical Center are among the first in the country to use the technology to gain extraordinary views of the human anatomy.
This Kaiser Health News story by David Gulliver, produced in partnership with Health News Florida, explores how the impact of changes to Medicare Advantage will differ from place to place across the country.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
› Verified 7 days ago
| Entity Name | Providence Health & Services Mt |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144319138 PECOS PAC ID: 6608786306 Enrollment ID: O20031229000787 |
News Archive
MR Solutions' latest compact preclinical, multi-modality MRI systems will be on display at the 14th European Molecular Imaging Meeting (EMIM 2019) being held at the Scottish Event Campus in Glasgow on 19 to 22 March, 2019.
The startlingly clear images displayed by high definition televisions have attracted the attention of sports enthusiasts, movie fanatics, and video gamers. Now some surgeons at the Virginia Commonwealth University Medical Center are among the first in the country to use the technology to gain extraordinary views of the human anatomy.
This Kaiser Health News story by David Gulliver, produced in partnership with Health News Florida, explores how the impact of changes to Medicare Advantage will differ from place to place across the country.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
› Verified 7 days ago
| Entity Name | Pathology Consultants Of Western Montana Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700831021 PECOS PAC ID: 2769377548 Enrollment ID: O20040219000769 |
News Archive
MR Solutions' latest compact preclinical, multi-modality MRI systems will be on display at the 14th European Molecular Imaging Meeting (EMIM 2019) being held at the Scottish Event Campus in Glasgow on 19 to 22 March, 2019.
The startlingly clear images displayed by high definition televisions have attracted the attention of sports enthusiasts, movie fanatics, and video gamers. Now some surgeons at the Virginia Commonwealth University Medical Center are among the first in the country to use the technology to gain extraordinary views of the human anatomy.
This Kaiser Health News story by David Gulliver, produced in partnership with Health News Florida, explores how the impact of changes to Medicare Advantage will differ from place to place across the country.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Adam Alan Vanregenmorter, MD Po Box 17528, Missoula, MT 59808-7528 Ph: (406) 728-8420 | Mr Adam Alan Vanregenmorter, MD 2827 Fort Missoula Rd, Missoula, MT 59804-7408 Ph: (406) 327-4330 |
News Archive
MR Solutions' latest compact preclinical, multi-modality MRI systems will be on display at the 14th European Molecular Imaging Meeting (EMIM 2019) being held at the Scottish Event Campus in Glasgow on 19 to 22 March, 2019.
The startlingly clear images displayed by high definition televisions have attracted the attention of sports enthusiasts, movie fanatics, and video gamers. Now some surgeons at the Virginia Commonwealth University Medical Center are among the first in the country to use the technology to gain extraordinary views of the human anatomy.
This Kaiser Health News story by David Gulliver, produced in partnership with Health News Florida, explores how the impact of changes to Medicare Advantage will differ from place to place across the country.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
› Verified 7 days ago
Dr. Carl Muus, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2825 Stockyard Rd, Building I200, Missoula, MT 59808 Phone: 406-728-8420 Fax: 406-541-8430 | |
Dr. Nicole Marie Finke, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-327-4179 Fax: 406-327-4515 | |
Dr. Christopher Michael Sjostrom, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-327-4330 | |
Dr. Marie Boyd, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2825 Stockyard Rd, Building I200, Missoula, MT 59808 Phone: 406-728-8420 Fax: 406-541-8430 | |
Dr. Bruce Britton, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2825 Stockyard Rd, Building I200, Missoula, MT 59808 Phone: 406-728-8420 Fax: 406-541-8430 | |
Dr. Sunil Kumar Prashar, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 2679 Palmer St, Missoula, MT 59808 Phone: 406-329-1178 | |
Kristine Krager Muus, Pathology Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Pathology Department, Missoula, MT 59802 Phone: 406-542-0001 |